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ABBREVIATIONS 
 
 
 
ADP     adenosine diphosphate 
AP-1    activation protein-1 
ASA    acetylsalicylic acid 
ATP    adenosine triphosphate 
COX    cyclooxygenase 
DAG    diacilglicerol 
DNA    dezoxyribonucleic acide 
EMSA   electrophoretic mobility shift assay 
ECG    elecrocardiograph 
FV    ventricular fibrillation 
GSH    reduced glutathione 
HSP    heat shock protein 
iNOS    inducible nitric oxide synthase 
Ik-B    inhibitor kappa-B 
IKK    inhibitor kappa kinase 
IP3    inositol triphosphate 
LAD    left anterior descendens coronary artery 
LV    left ventricle (of the heart) 
MAP kinase   mitogén aktivated protein kinase 
MDA    malondialdehyde 
MnSOD    manganese superoxide-dismutase 
MPG    N-2-mercaptoproprionylglycine 
NFkB    nuclear factor-kappaB  
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NO    nitric oxide 
NSAID   non-steroid anti-inflammatory drugs 
OFR    oxygen free radicals 
ONOO   peroxinitrit 
PC    preconditioning 
PIP2    phosphatitil/inositol/ diphosphate 
PKC    protein kinase C 
PLC and PLD  phospholipase C and D 
ROI    reactive oxygen intermediers 
SOD    superoxide dismutase 
SWOP   second window of protection 
TyrK    tyrozin kinase 
TTC    triphenyltetrazolium chloride
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1. INTRODUCTION 
 
 
 
It is now 11 years since the phenomenon termed "ischaemic preconditioning" was formally 
recognised 1. There can be little doubt that our understanding of the mechanisms underlying 
the pathogenesis of ischaemia-reperfusion injury has been enhanced significantly by the 
extensive research stimulated by interest in endogenous myocardial protection. In the basic 
experimental setting, the triggers, mediators and effectors of the preconditioning phenomenon 
are being extensively investigated. The results of recent clinical experiments suggest that 
preconditioning can protect against ischaemic injury, although at this stage they must be 
interpreted with caution.  
 
1.1 HISTORY OF ISCHAEMIC PRECONDITIONING 
 
In 1986 Reimer et al.2 reported a series of experiments in the dog heart designed to dissect the 
contributions of ATP depletion from catabolite accumulation in the genesis of lethal 
ischaemic injury. Their experimental model involved repetitive brief ischaemic episodes, 
working on the premise that each ischaemic episode would cause cumulative ATP depletion 
while the intermittent reperfusion would wash out ischaemic catabolites. To their surprise 
they found that, following the initial ischaemic period, ATP levels were not depleted further 
by subsequent similar ischaemic challenges. They also noted that no infarction occurred in six 
of the seven dogs studied. This result was contrary to the previously accepted view that 
repetitive ischaemia would cumulatively lead to infarction. The observation led the same 
group 3 to test the hypothesis that the preservation of high energy phosphates was due to a 
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slowing of consumption during ischaemia associated with a rapid and protective adaptation of 
the myocyte. They tested this hypothesis by subjecting the myocardium to four 5 minute 
coronary occlusions, separated by 5 minutes' reperfusion, before a sustained 40 minute 
ischaemic insult. They found that the preceding brief periods of ischaemia and reperfusion 
were protective, reducing infarct size to 25% of that seen in the control group. This 
phenomenon was termed "preconditioning with ischaemia". Following these initial studies, 
the protection obtained has been further characterised both in terms of time course and 
various end-points of cellular injury. 
 
1.2. CLASSIC ISCHAEMIC PRECONDITIONING 
 
Brief episodes of ischaemia-reperfusion protect the myocardium from the damage induced by 
subsequent more prolonged ischaemia. When first described by Murry et al.4 such ischaemic 
preconditioning was elicited by brief coronary occlusion, and the endpoint was reduced 
infarct size. This protection, termed classic preconditioning, appears to be an acute and 
immediate response lasting not more than a few hours. Soon, however, a variety of 
preconditioning stimuli were uncovered including hypoxia5, rapid cardiac pacing6, 7  , thermal 
stress8, stretch9, and various pharmacological agents. Also various endpoints of ischaemic 
preconditioning have been used: ischaemic preconditioning protects against infarction in all 
species tested so far, and there is also evidence that it might be operative in human 
myocardium10. Ischaemic preconditioning also reduces the extent of apoptosis11,  12. Other 
studies have used recovery of contractile functions as an end point of ischaemic 
preconditioning. Although it appears logical that less infarcted myocardium in preconditioned 
hearts should result in improved regional and subsequently global function, ischaemic 
preconditioning does not improve regional myocardial function within the first hours of 
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reperfusion (thus it does not attenuate stunning) in animal models13, 14, 15. However, with 
longer reperfusion ischaemic preconditioning diminishes adverse left ventricular remodelling 
following infarction and improves long-termfunctional recovery in chronically instrumented 
rabbits16. Iscaemic preconditioning protects against arrhythmias in mice17, rats18, rabbits19, 
and dogs20. In pigs, however, ischaemic preconditioning not only fails to reduce the incidence 
of ventricular fibrillation during ischaemia-reperfusion, but even accelerates the onset of 
ventricular fibrillation during sustained ischaemia and decreases the ventricular fibrillation 
threshold21. 
 
This manuscript does not want to go into details of the cellular pathways leading to classic 
preconditioning. It is believed that PKC phosphorlates other kinase, including p38 mitogen 
activator protein kinase (p38 MAP kinase), and eventually leads to the opening of the 
mitochondria ATP-sensitive potassium (KATP) channels. In support of this theory, studies 
using KATP channel inhibitors such as glibenclamide or 5-hydroxydecanoate have blocked 
protection (10,11). KATP channels open when intracellular ATP concentration falls. An influx 
of potassium ions follows, shortening action potential duration and reducing the influx of 
calcium ions into the cell. KATP channel opening is believed to be the key effector in 
conferring early protection to the myocardium. There are emerging views as to the 
mechanism behind this form of protection.  
 
 
1.3. DELAYED PRECONDITIONING 
 
In addition to the initial phase of protection in 1993 two separate studies by Kuzuya et al. and 
Marber et al. both observed that, a second wave of protection appears 24 hours following the 
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preconditioning protocol22 23. This second wave of protection is now referred to as the second 
window of protection (SWOP), late preconditioning or delayed preconditioning. SWOP has 
certain characteristics, distinct from classic preconditioning. It appears gradually, yet lasts as 
long as 72 hours or more.  
Early studies about the late preconditioning studies took infarct size reduction as the end point 
of cardioprotection, and there was little data regarding any delayed antiarrhythmic effect in 
the second window. Végh et al. in 1994published a study that positively confirmed delayed 
protection against reperfusion arrhythmias in the canine heart, using ventricular rapid pacing 
to globally precondition the heart24. 
 
1.3.1. TRIGGERS OF DELAYED PRECONDITIONING 
As with investigations of classic preconditioning, the mechanisms of delayed preconditioning 
may be conceptually divided into `upstream' and `downstream' components. In the rabbit, 
adenosine A1 receptor activation during preconditioning is an important trigger of delayed 
protection against infarction. Adenosine receptor blockade during preconditioning abolishes 
the protective response 24 hours later25 and conversely, stimulation of A1 receptors with a 
selective agonist results in marked protection against infarction 24–72 hours later26 27 28. In 
the pig, delayed preconditioning against stunning does not appear to involve adenosine, but 
free radicals and nitric oxide are important triggers 29 30. At present it is not possible to say if 
this divergence is due to differences in experimental endpoint (infarction versus stunning) or 
species (rabbit versus pig).  
Since it is clear that delayed myocardial protection can be induced by means other than 
transient ischaemia, investigation of these stimuli may ultimately be relevant, not only for our 
understanding of the mechanisms of delayed preconditioning but to the development of 
practical therapeutic approaches. For example, bacterial endotoxin treatment is known to 
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induce delayed myocardial protection, probably by upregulating various cytoprotective 
proteins, including antioxidants and inducible nitric oxide synthase. The endotoxin derivative 
monophosphoryl lipid-A induces myocardial protection 24 hours after administration and the 
opening of the KATP channel may be integral to this late protective response31. There is 
considerable evidence that bradykinin (synthesised by endothelial cells) is involved as a 
trigger in preconditioning, and may contribute to the cardioprotective effects of ACE 
inhibitors32 33. ACE inhibition results reduced breakdown of bradykinin, thus could start up 
the signaling cascade leading to delayed protection34. 
 
1.3.2. THRESHOLD HYPOTHESIS OF TRIGGERING THE ISCHAEMIC 
PRECONDITIONING 
Not all combinations and durations of ischaemia and reperfusion will trigger the 
preconditioning phenomenon and protect ischaemic myocardium. There appears to be a 
critical threshold. Very short preconditioning ischaemia with subsequent reperfusion prior to 
the index ischaemia has no protective effect in pigs35 and humans36. Above this threshold the 
protection conferred by ischaemic preconditioning is independent from the intensity of the 
preconditioning stimulus. There is a definite and fairly rigid time frame for ischemic 
preconditioning. Somehow the myocardium `remembers' that it has been preconditioned by a 
brief ischemic period, which has occurred up to several hours before the index ischemia. The 
exact nature and location of this memory is one of the great, unsolved mysteries of ischemic 
preconditioning.  
 
1.2.3. SIGNALLING ASPECTS OF DELAYED PRECONDITIONING 
Activation of PKC appears to be a crucial intermediate step since pharmacological inhibition 
of PKC during the preconditioning stimulus abolishes protection 24 hours later in the rabbit 
 12
infarct model37. Direct measurements of PKC activity and translocation have not been widely 
studied so far but Parratt's group have recently provided evidence that sustained PKC-  
translocation to the membrane fraction occurs in the hearts of dogs subjected to rapid cardiac 
pacing38, a stimulus that induces delayed protection against ischaemia-reperfusion 
arrhythmias. It has also been reported that brief repeated periods of coronary artery occlusion 
in the conscious rabbit cause the translocation of PKC- 39, and that this can be blocked with 
chelerythrine40.  
The involvement of other parallel and downstream kinases is under investigation. 
Considerable interaction exists between PKC and other kinase systems including tyrosine 
kinase and MAP kinase cascades. Tyrosine kinase activation may be an obligatory component 
of the signalling cascade since administration of genistein during preconditioning in rabbits 
abrogates the delayed anti-infarct effect41. Interestingly, delayed protection induced by 
adenosine A1 agonist in rabbits is dependent on both PKC and tyrosine kinase activation since 
protection can be abolished by pretreatment with either chelerythrine (a PKC inhibitor) or 
lavendustin-A (a tyrosine kinase inhibitor)42. The interactions of these complex signalling 
systems and their involvement or interaction with membrane channels or new protein 
synthesis still needs to be evaluated. 
 
The transcription factor nuclear factor-kappaB (NFkB) appears to be a critical regulator for 
gene expression induced by diverse stress signals including mutagenic, oxidative and hypoxic 
stresses. NFkB is a ubiquitous transcription factor, which is translocated in response to 
oxidative stress from its inactive cytoplasmic form by releasing the inhibitory subunit 
Inhibitor kappaB (IkB) from NFkB43 44. Activation of NFkB is likely to be involved in the 
induction of gene expression associated with the ischaemic adaptation, since this transcription 
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factor has recently been found to play a crucial role in the regulation of ischaemia-
reperfusion-mediated gene expression and consecutive protein synthesis45. 
 
1.2.4. PROTEIN EFFECTORS OF DELAYED PROTECTION 
A fundamental difference between classic and delayed preconditioning may be in the means 
by which cardioprotection is conveyed. In the former, KATP channels are suspected to be the 
end-effectors, in the delayed preconditioning newly synthesised cardio-protective proteins are 
claimed to convey protection. The time course of delayed preconditioning is suggestive of a 
mechanism involving new protein synthesis.  
Two early reports raised the possibility that the delayed phase of protection involves either 
increased activity of manganese-superoxide dismutase (SOD)46 or elevation of the myocardial 
content of the major inducible heat shock protein, HSP7247. Both proteins are stress-induced 
proteins that have cytoprotective properties. Manganese-SOD is a mitochondrial antioxidant 
which detoxifies superoxide anions. HSP72 is a chaperone protein involved in regulation of 
protein folding, transport and denaturation during the cellular response to injury. Hoshida et 
al.48 described the temporal dynamics of manganese-SOD activity following preconditioning 
in canine myocardium and reported a biphasic pattern of enzyme activity over a 24 hour 
period similar to the biphasic timecourse of the anti-infarct effect49. Similarly, myocardial 
content of HSP72 was elevated in rabbits 24 hours after preconditioning, a time when 
increased tolerance to infarction was observed50. Relationships between enhanced ischaemic 
tolerance and stress-inducible cytoprotective protein activity have been pursued most 
convincingly in gene transfection studies51 52, antisense oligonucleotide studies53 and studies 
with transgenic mice constitutively over-expressing human HSP7254. These studies tend to 
suggest, but do not confirm, that the appearance of the delayed protection could be related to 
changes in activities of stress-inducible cytoprotective proteins in preconditioned 
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myocardium. However, it is important to note that since the regulation of a large number of 
proteins is altered by sublethal ischaemia, it is likely that delayed preconditioning involves 
other proteins in addition to anti-oxidants and heat shock proteins. A number of new gene 
products not yet identified may be involved and techniques such as differential gene display 
and other advanced molecular techniques will be very relevant to future research directions. 
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2. AIMS AND HYPOTHESIS 
 
 
In the last decade the extensive research in the field of ischaemic preconditioning has greatly 
extended our understanding of the signalling mechanism of cardiac adaptation. Although 
many questions are yet to be elucidated, especially with regard to the role of transcription 
factors in the second window of protection, it remains one of the most powerful experimental 
tools in cytoprotection that may one day translate into a clinical reality.  
 
In the first part of our investigations we aimed to monitor the time fluctuaion of the 
activation of two transcription factors, nuclear factor (NF)-kB and activation protein 
(AP)-1, which are conferred to play essential role in the gene-expression induced by the 
ischaemic preconditioning. We aimed to measure the DNA binding activity of these two 
transcription factors in the nuclear fraction of cardiomyocytes in different, definitive times of 
the reperfusion following the stimulus of ischaemic preconditioning. 
 
In the second part of our investigations, we aimed to define the activation level of NFkB 
after repeated number of preconditioning stimuli. The protective effect of delayed 
preconditioning is an “all or nothing” response: the strength of the evoked cardioprotection is 
independent from the strength (duration and number of the ischaemic-reperfusion cycles) of 
the preconditioning (PC) stimuli. We hypothetized that the activation of the transcription 
factors in the delayed adaptation is also independent from the PC stimulus, thus the all or 
nothing response evolves in the level of the triggers.  
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We also aimed to investigate the role of oxygen free radicals (OFR) in the signaling 
cascade of this adaptive process leading to the induction of NFkB. The Department of 
Experimental Surgery in Pécs has many years of experience investigating free radicals in 
relation to ischaemic-reperfusion, especially in heart tissue. This provided us with the ideal 
opportunity to set upon the task of examining the role of OFR in delayed IPC. Numerous 
studies suggest that OFRs act as trigger and as mediators of delayed ischaemic 
preconditioning in an additive interaction with the other triggers. Accordingly, we aim to 
measure the NFkB activation after repeated cycles of preconditioning ischaemia-reperfusio 
after blocking the OFRs.  To monitor the haemodynamic parameters of the heart during the 
preconditioning and in the reperfusion period we measure the heart rate, systolic and diastolic 
heart pressure and calculate the rate pressure product of the animals. 
 
It has been demonstrated that the nonsteroid anti-inflammatory drog, aspirin - which is widely 
used for patient with ischaemic heart disease - in vitro blocks the activation of the 
transcription factor NFkB, which is necessary for the delayed cardiac adaptation. In the third 
part of our investigations we aimed to demonstrate that aspirin (acetylsalicylic acid, 
ASA), used in low and medium concentration do not inhibit the activation of NFkB in 
vivo in the preconditioned myocardium. Furthermore we investigate the effect of ASA on 
the delayed cardioprotection against myocardial infarction. 
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3. DYNAMISM OF ACTIVATION OF NUCLEAR FACTOR-κB AND ACTIVATION 
PROTEIN-1 IN THE SIGNALLING OF DELAYED MYOCARDIAL 
PRECONDITIONING 
 
 
3.1. INTRODUCTION 
 
The sublethal ischemic stress initiate a complex signal transduction cascade that modulates 
the activation of the severe transcription factors, which lead up to expression of 
cardioprotective genes. Recent studies assume, that the activation and translocation of Nuclear 
Factor (NF) -κB and Activation Protein-1 (AP-1) is a key component in the signal 
transduction mechanism of ischaemic preconditioning55,56.  
 
3.1.1. NFkB IN THE SIGNALLING OF ISCHAEMIC PRECONDITIONING 
NF-kB is a redox sensitive transcription factor involved in transcription of proteins in 
response to mutagenic, oxidative and hypoxic stress57 58. Under normal physiologic conditions 
NF-kB is found in the cytoplasm of cells in an inactive form in association with the inhibitor 
IkappaB-alpha. Upon cellular stress stimulation, IkB-alpha is phosphorylated on two serine 
residues (S32 and S36), ubiquitinated, and degraded by a proteosome-dependent pathway, 
allowing active NF-kB to translocate to the nucleus59, 60. NF-kB translocation leads to 
expression of a large number of NF-kB related genes, encoding various signaling and defense 
proteins, which are supposed to bring the cellular protection in the late preconditioning61.  
In contrast to the role NF-kB activation has in the destructive events of inflammation, NF-kB 
also mediates the expression of cytoprotective proteins (Heat Shock Proteins) that block 
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apoptosis or inhibit inflammation in response to several types of cellular stress62.  In a 
negative feedback manner, these cytoprotective proteins inhibit NF-kB63. 
The NF-κB pathway displays the capacity to activate, in a cell- and stimulus –specific 
manner, only a subset of the total repertoire of NF-κB –responsive genes. The seemingly 
promiscuous nature of NF-κB activation poses a regulatory quagmire as to how specificity is 
achieved at the level of gene expression. Rapid growth in our understanding of signal 
transduction in general, and NF-κB in particular, provide intriguing insight as to how this may 
occur. 
 
3.1.2. AP-1 IN THE SIGNALLING OF ISCHAEMIC PRECONDITIONING 
Ap-1 is another well-characterized eukaryotic transcription factor that is highly regulated by 
the redox status of the cell. It is composed of various subunits (jun, fos, and Fra) as dimers, 
which recognize with different affinities the AP-1 DNA-binding site. Through the mechanism 
of reactive oxigen intermediates (ROI) – generated by ischaemia-reperfusion – induction of 
AP-1 is not clear, alteration of cell thiol redox status has been shown to induce c-fos and c-jun 
expression, and phosphorylation of jun proteins. Many factors including ionizing radiation, 
cytokines, oxidative stress, and growth factors lead to AP-1 activation. Similar to NF-κB, 
activation of AP-1 induces expression of a variety of genes whose protein products may either 
protect the cells from, or make the cells more susceptible to oxidative stress. Oxidative stress 
caused by the brief ischaemia-reperfusion of preconditioning induce NF-κB and AP-1 
activation, both of them activate pro- and anti-apoptotic signals in vivo in the myocardium.  
For understanding the role, and the detailed regulation of these transcription factors in the 
phenomenon of ischaemic PC, the purpose of this study was to examine the time fluctuation 
of NF-κB and AP-1 levels in the preconditioned myocardium. We measured the DNA binding 
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activity of NF-κB and AP-1 at various times after brief ischaemic episode in reperfused 
myocardium.  
 
3.1.3. AIMS 
Because the exact mechanism of the activation of these factors is still not clear in the 
signaltransduction of the ischaemic preconditioning of the myocardium, we aimed to monitor 
the time fluctuation of the NFkB and AP1 induction in an in vivo animal model. We aimed to 
follow the changes in the activation rate of NFkB and AP1 in the reperfusion period after 
ischaemic preconditioning stimuli. 
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3.2. MATERIALS AND METHODS 
 
The present study conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No.85-23,revised 1996) 
and was approved by the local institutional Committee on Animal Research of Pécs 
University (BA02/2000-29/2001). 
 
3.2.1. SURGICAL PREPARATION 
A marginal ear vein was cannulated in 42 New Zealand White rabbits weighing 2,6-3,3 kg 
(mean 2,8kg), after local anaesthesia was induced using lidocaine cream. The animals were 
anaesthetised with intravenous (iv.) xylazine (6mg/kg), ketamine (6 mg/kg) and propofol 
(10mg/kg). The trachea was intubated (tube 3 mm internal diameter) and the lungs were 
ventilated (Sulla 808, Drager , Lübeck, Germany) at a frequency of 30-35 breaths/min and a 
tidal volume of 15-20 ml. Anaesthesia was maintained by inhalation of isoflurane (2-4 Vol.%) 
and nitrous oxide (50 Vol.%). 
The chest was opened by midline sternotomy. A 5-0 prolene (Ethicon 5/0, 1-metric, TF) 
ligature was passed around the left anterior descending (LAD) coronary artery and through a 
snare. In general the site of vessel encirclement was on the long axis of the left ventricle 
towards the apex approximately one-fourth of the distance from the atrioventricular groove to 
the left ventricular apex. Fifteen minutes after completion of surgical preparation animals 
were heparinized with 500 U of heparin sodium. Temperature was measured inside the 
pericardial cradle (Siemens Sirem, Digital Thermometer, Düsseldorf, Germany) and 
maintained between 38,3˚C and 38,7˚C by adjusting a heating pad and an infrared lamp. 
In the ischaemic preconditioned (PC) groups the snare was tightened for 5 min, thereby 
inducing occlusion of the coronary artery.  Myocardial ischaemia was readily discernible by 
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the development of a dusky, bulging region of myocardium (careful note was made of 
anatomic landmarks of this region). The effectiveness of this manoeuvre was verified by the 
appearance of epicardial cyanosis and by the immediate occurrence of ST-segment elevations 
in the electrocardiogram (ECG) (Siemens Sirecust 1260, Düsseldorf, Germany). At the end of 
the 5-min period of coronary artery occlusion, the suture was released and removed to ensure 
proper reperfusion, which was verified by the disappearance of the ECG changes within 5 min 
in every animal. 
 
3.2.2. EXPERIMENTAL PROTOCOL 
In our experiments the animals (42 rabbits) were randomly listed in 7 groups. In control 
animals (group 1, 6 animals) the heart was excised right after thoracotomy and tissue sample 
was taken from the untreated heart. In the preconditioned groups, after 5 min ischaemic 
period animals were assigned to 10 min (group 2, 6 animals), 30 min (group 3, 6 animals), 
1hour (group 4, 6 animals), 2 hours (group 5, 6 animals), 3 hours (group 6, 6 animals), or 4 
hours (group 7, 6 animals) reperfusion period (R) before taking tissue sample from the 
ischaemic zone of the heart. (figure 1.) 
 
After the experimental period the heart was rapidly excised and rinsed in ice-cold 
physiological saline. The ischaemic zone was excised on the basis of the previously defined 
landmarks. The tissue was snap frozen in liquid N2, and stored for not more than 3 days at -
82C before EMSA analysis. 
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3.2.3. ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
100 mg tissues were homogenized in 1 ml TE buffer (1.5 mM EDTA, 0.01 M Tris Base, pH 
7.4) containing 10 µM PMSF. Nuclei were separated from cytosol by centrifugation at 1400 
xg for 20 min at 4°C, and this separation procedure was repeated for 3 times. The last pellet 
was resuspended in 2 volumes of buffer containing 20 mM HEPES pH 7.9, 25% glycerol, 420 
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, protease inhibitors (Complete 
Mini, Boehringer Mannheim, Germany) and placed on ice for 20 min. After 10s 
centrifugation the supernatants were saved, alliquoted and stored.  
Protein concentration was determined with the Bio-Rad Protein Assay kit. 5’-end labelling of 
oligonucleotides was performed using [γ-32P]-ATP and T4 polynucleotide kinase (Amersham 
Pharmacia Biotech Inc., UK) according to the manufacturer’s protocol. 
20 µg nuclear proteins were mixed with 1 µg poly(dl-dC), 100 ng non-specific single-
stranded oligonucleotide and 4 µl buffer containing 10 mM HEPES pH 7.5, 10% glycerol, 1 
mM EDTA, 100 mM NaCl. After 15 min incubation at room temperature the mixtures was 
1 
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4 
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6 
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Figure 1. Experimental groups with different time of reperfusion. 
 =5 min ischaemia 
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completed with 2 µl, approximately 100 000 cpm of 32P oligonucleotide and then incubated 
for another 30 min. DNA-protein complexes were electrophoresed in a 5% non-denaturating 
polyacrylamide the gel using a Tris Base, Borate, EDTA buffer system (pH 8.3) for 2.5 h at 
200 V. Gel was dried and were quantitated using an image scanning densitometer (Cyclone 
Phosphorlmager System, Packard I. C. USA).  
 
3.2.4. STATISTICAL ANALYSIS 
For statistical analysis EMSA pictures were appreciate with Colim 2000 Color Image 
Measuring (Pictron Kft, Hungary) densitometry software. The data (mean ± SEM) for levels 
of expression of individual protein (EMSA) were subjected to analysis of variance with post 
hoc Dunnett’s 1-tailed t-tests (NF-κB, and AP-1 EMSA), and two-sample Student’s t-test for 
significance. P < 0,05 was considered significant. 
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3.3. RESULTS 
 
3.3.1. TIME COURSE OF NF-KB ACTIVATION 
Fig. 2. shows changes in NF-kB levels in preconditioned myocardium after various 
reperfusion (R) times. Specificity of the signal was verified in a competition assay wherein 
the signal detected by labeled NF-kB was abolished, when the protein homogenate was 
preincubated with excess unlabeled NF-kB oligo before the addition of labeled NF-kB. The 
signal was not abolished, when the competition assay contained excess unlabeled non NF-kB 
binding oligonucleotide.  Low and consistent levels of NF-kB were detected in normal 
myocardium (untreated: group 1) at steady state. Significantly higher levels were detected at 
30 min R (group 3) in all 6 animals (densitometry: 2,35-fold; p<0.0001 vs. controls), and then 
fell to lower state at 1 h R. Again at 3 h R (group 6), the levels rose significantly higher (2,59-
fold; p<0.0001). At 4 h R the levels decreased to basic rate, indicating a biphasic regulation 
(with an emphatic up- and downregulation) of NF-kB in preconditioned myocardium.  
 
3.3.2. TIME COURSE OF AP-1 ACTIVATION 
Fig. 3. shows changes in AP-1 levels in control (untreated) and in preconditioned 
myocardium. After a weak signal elevation at 30 min R, significant increase of AP-1 levels 
were detected at 1 h R (group 4) (p<0.001). Though the levels declined gradually, they were 
still signal at 2, 3, and 4 h R. Preincubation of protein homogenate with excess unlabeled AP-
1 consensus oligo abolished specific signals obtained by labeled AP-1, demonstrating the 
specificity of signals. Signal specificity was established the above mentioned way in all cases. 
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Figure 2. Nuclear levels of NFkB after different reperfusion period in the 
preconditioned myocardium. (time course). Activated NF-kB bands (a p50/p65 
heterodimer and a p50 homodimer) are shown. EMSA analysis.(left) Densitometry 
measurements expressed as percent of control. * p<0,0001 v control.(right) 
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Figure 3. Nuclear levels of AP-1 transcription factor after different reperfusion 
period in the preconditioned myocardium. (time course) EMSA analysis. (left) 
Densitometry measurements expressed as percent of control. * p<0,001. (right) 
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3.4. DISCUSSION 
 
Recurrent episodes of myocardial ischaemia are commonly observed in patients with coronary 
artery disease who suffer from frequent angina pectoris or angioplasty of the left anterior 
descending coronary artery. Reversibly injured myocardium (by short episode of ischaemia 
followed by another short period of reperfusion) renders the heart more resistant to a longer 
ischaemic-reperfusion period. Such adaptation – ischaemic precondition (PC) - is mediated 
through the upregulation of the heart’s own cellular defense via the accumulation of 
intracellular mediators and reprogramming of gene expression. Recent studies suggest that 
NF-kB and AP1 transcription factors have a possible role in the signaltransduction pathways 
of this cytoprotection are resulted from ischaemic adaptation. 
 
3.4.1. DYNAMISM OF NFkB ACTIVATION 
The results of our experiments show that there is a biphasic activation of NF-kB in the 
preconditioned myocardium, with increased levels at an early time point (30 min), and again 
at 3 hour R.  There is presumed to be two different ways leading to the early NF-kB activation 
after ischaemic PC. Through receptor-dependent triggers (AdenosineA1 agonists64, opioid δ1 
agonists65, bradykinin, prostaglandins, norepinephrine, angiotensin, endothelin): the receptor 
is coupled through G proteins to, among others, phospholipase C (PLC) and D (PLD). PLC 
catalyzes the hydrolysis of membrane inositol-containing phospholipids into inositol 
trisphosphate and diacylglycerol (DAG)66. DAG stimulates the translocation and activation of 
protein kinase Cε (PKCε). The onset of the PLC reaction is typically very rapid, and DAG 
production is short-lived, peaking at 30 s67. PKCε activation then triggers a complex signaling 
cascade that involves Src and-or Lck tyrosine kinases and probably other kinases, leading to 
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phosphorylation of Inhibitor-κBα (IκBα) and to mobilization (nuclear translocation) and 
activation of the transcription factor NF-kB68. 
Another possible way of NF-kB activation in ischaemic PC is came off through the increased 
production of nitric oxide (most likely via eNOS) and .O2- (leading to formation of secondary 
reactive oxygen species (ROS)) after a brief episode of myocardial ischaemia/reperfuson69. 
Both NO and  .O2- derived ROS could directly activate the ε  isoform of PKC via nitrosylation 
and oxidative modification, respectively; alternatively, NO and .O2- are known to react  to 
form ONOO- which, in turn, could activate PKCε. Thus PKC is thought to be a critical 
component in both pathways70,71.  
 
Ischaemic PC has recently been found to activate Janus Activated Kinase 1 and 2 (JAK1, 
JAK2) with a subsequent tyrosine phosphorylation and activation of STAT1 and STAT3, 
which is essential for iNOS upregulation. Binding of NF-kB and STAT1/3 to the inducible 
Nitric Oxide Synthase (iNOS) promoter results in transcriptional activation of the iNOS gene 
and lead to synthesis of new iNOS protein (eNOS-dependent iNOS induction).  iNos –derived 
NO is supposed to make a second wave of PKCε activation, leading to the late phase of NF-
kB activation and translocation72.  
 
The other possible explanation of the late increase in NF-kB activation might be the feed-back 
mechanism of NF-kB induced pro-inflammatory cytokines (TNFα, IL-1β). After ischaemia-
reperfusion, even in case of ischaemic preconditioning, NF-kB can induce TNFα and IL-1β 
gene expression73,74. Trough a certainly unknown mechanism these cytokines generate a mass 
of ROI in the myocardium, which can - via the above mentioned pathway – newly activate 
NF-kB in the cytoplasm and lead to a delayed wave of nuclear translocation of this 
transcription factor. TNFα and IL-1β can also start up a signaling pathway leading to IkB 
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phosphorylation, - and thus NF-kB activation - through cell membrane receptors75. A number 
of signal transduction proteins have been identified as associated with these receptors, 
including TNF-receptor associated factors 2 and 6 (TRAF2 and 6) death domain-containing 
proteins (TRADD and FADD), kinases associated with IL-1 receptor (IRAK1 and 2, and 
MYD88). These kinases phosphorylate members of the IkB family at specific serines within 
their N-termini, leading to site-specific ubiquitination and degradation of NF-kB by the 26S 
proteosome. This circle cascade (NF-kB→TNFα, IL-1β→NF-kB feedback) might also be an 
explanation of the biphase activation of NF-kB after ischaemic PC76. (figure 4.) 
 
 
3.4.2. DYNAMISM OF AP-1 ACTIVATION 
The second observation of our study is the detection of increased AP1 levels in the 
preconditioned myocardium. In contrast to NF-kB, where after an initial increase at 30 min a 
second peak was observed at 3 hR, AP1 levels increased in a monophasic manner at 1 h R. 
Though we did not measure the levels of AP1 during the ischaemic period, in various in vitro 
systems, substantial increase in AP1 levels was demonstrated during hypoxic conditions. In a 
cancerous cell line (HeLa), Rupec and Baeuerle have shown increased NF-kB activity within 
15 min after initiation of reperfusion, while increased AP1 was detected during hypoxia 
itself77. They argued that during reoxygenation, increased intracellular ROI activate existing 
NF-kB by dissotiation from its inhibitor IkB, while low levels of free radicals during hypoxia, 
a condition similar to that observed during antioxidant treatment, induced AP1. 
Because both NF-kB and AP1 are activated by cytokines such as IL-1 and TNFalpha, the 
positive synergy between NF-kB and the subunits of AP1 might have important implications 
for both immune and inflammatory responses. Stein et al. have shown functional cross-
coupling of NF-kB p65 and AP1 families of transcription factors, resulted in increased DNA 
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binding activity of NF-kB. Both s-fos and c-jun synergised with NF-kB by physically 
interacting with p65 subunit78. Whether such interaction exists in preconditioned myocardium 
is not known.  
 
3.4.3. CONCLUSION 
From our study we conclude, that after the ischaemic preconditioning stimuli the activation of 
NFkB is biphasic with peak levels at 30min and at 3 hour of reperfusion in the preconditioned 
myocardium. The activation rate of AP1 increased monophasically, with peak level at 1 hour 
of reperfusion. These data show that the activation of NFkB and AP1 have a specific time 
curve in the signaling of endogenous cardioprotection. 
 
 
 
 
 
 
 
Figure 4.(next page) Shematic representationof the intracellular signaltransduction of 
ischaemic preconditioning. (NO-nitric oxide; ROI-reactive oxygen intermediers; ONOO-
peroxinitrit;  PLC and PLD-phospholipase C and D; PIP2-phosphatitil/inositol/ diphosphate; 
Ip3-inositol triphosphate; DAG-diacilglicerol; PKC-protein kinase  C; IKK-inhibitor  kappa 
kinase; MAP kinase-mitogén aktivated protein kinase; TyrK-tyrozin kinase; NFkB-nuclear 
factor-kappaB; iNOS-inducible nitric oxide synthase; MnSOD- manganese  superoxide-
dismutase) 
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4. THE ROLE OF OXYGEN FREE RADICALS IN THE ACTIVATION OF NF-KB IN 
THE PRECONDITIONED MYOCARDIUM 
 
 
 
4.1. INTRODUCTION 
 
4.1.1.GENERAL BACKGROUND 
Oxygen free radicals are highly reactive molecules with an unpaired electron, associated 
widely with ischaemic-reperfusion injury79 80 81. Although better known for their toxicity, 
when in large quantities they overwhelm the endogenous antioxidant systems, recently it has 
been suggested that at low concentrations they can modulate survival functions within the 
cell. As previously mentioned Murry et al was the first to investigate their potential role as 
triggers of classic IPC82. Since then various species and models have been examined with 
conflicting results83 84 85 86, yet it is now generally acknowledged that oxygen free radicals can 
indeed induce early protection. Their role in delayed preconditioning however remains 
ambiguous.  
 
Since oxidative stress is known to induce the synthesis of cardioprotective proteins, such as 
antioxidant enzymes87 88 89 90 and HSPs91 92 93, and since these proteins could theoretically 
mediate the protection observed 24 hours after the initial ischaemic challenge, we 
hypothesized that the molecular adaptations, that lead through transcription factor NFkB 
activation to the late preconditioning, are initiated by the exposure to increased levels of 
reactive oxygen species during the preconditioning ischaemia. Low levels of free radicals can 
activate protein kinase C (PKC) directly94, thus through phosphorylation of Inhibitor Kappa 
Kinaseβ could induce NFkB activation and translocation to the nucleus. In addition, reactive 
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oxygen species may stimulate phospholipase D95, and the consecutive production of 
diacylglycerol could then also lead to the activation of PKC and to the induction of NFkB. 
 
4.1.2.AIMS 
One possibility, that has not been tested, is that the free radicals may act in concert with the 
other triggers of delayed preconditioning (adenosine, bradykinin etc.) in the induction of the 
transcription factor NFkB. If that were the case, then elimination of the free radical 
component following a single cycle preconditioning protocol, which is close to the threshold 
for protection, would cause a subthreshold stimulation for NFkB activation and loss of 
protection. On the other hand, if multiple cycles of preconditioning were employed then loss 
of only the free radical component would not be missed, because enough additional adenosine 
and bradykinin and other triggers would be released to reach threshold. In the present study 
we tested this hypothesis by examining the ability of the potent, cell-permeant radical 
scavenger, N-2-mercaptoproprionylglycine (MPG), to attenuate the induction of NFkB in 
ischaemic preconditioning induced by either a single or multiple episodes of ischaemia-
reperfusion in in situ rabbit hearts.  
In the first series of this study we aimed to investigate the activation rate of  NF-κB in cases 
of repeated cycles of ischaemic PC. In the second series we examined the NFkB activation 
after repeated cycles of PC in the presence of MPG. 
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4.2. MATERIALS AND METHODS 
 
All procedures were approved by the Local Committee on Animal Research, and were in 
accordance with recommendations by International Guiding Principles for Animal Research96 
(48) and was approved by the local institutional Committee on Animal Research of Pécs 
University (BA02/2000-29/2001). 
 
Adult New Zealand White rabbits (60 animals) of either sex with body weight ranging from 
2,6-3,3 kg (mean 2,8kg) were used. The rabbits were subjected to overnight fast prior to the 
experiments. Animals were pre-medicated with droperidol (1,5mg/kg) and atropine (1mg). 
Anesthesia was induced by intravenous (iv.) xylazine (6mg/kg), ketamine (6 mg/kg) and 
propofol (10mg/kg). Anesthesia was maintained with isoflurane (2-4 Vol.%) and nitrous 
oxide:oxygen (7:3) gaseous mixture. 
 
4.2.1. SURGICAL PROCEDURE 
After anesthesia we opened the chest by midline sternotomy. 5-0 prolene (Ethicon 5/0, 1-
metric, TF) ligature was circled around the left anterior descending (LAD) coronary artery. In 
general the site of vessel encirclement was on the long axis of the left ventricle towards the 
apex approximately one-fourth of the distance from the atrioventricular groove to the left 
ventricular apex. Fifteen minutes after completion of surgical preparation animals were 
heparinized with 500 U of heparin sodium.  
In the ischaemic preconditioned (PC) groups the snare was tightened for inducing occlusion 
of the coronary artery. At the end of the ischaemic period, the suture was released and 
removed to ensure proper reperfusion, which was verified by the disappearance of the ECG 
changes within 5 min in every animal. 
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In the second series of the study the animals N-2-mercaptopropionylglicine (MPG) was 
universally administered as a continuous infusion to block oxygen free radicals during the 
ischaemia- reperfusion period of preconditioning cycles. 
 
4.2.2. EXPERIMENTAL PROTOCOL 
In the first series of our study we aimed to measure the NF-kB activation after repeated cycles 
of ischaemia-reperfusion. The animals were selected in five groups, in each group there were 
6 rabbits. For NF-kB investigations the animals were subjected to either 1x-, 2x-, 3x-, or 4x-5 
min LAD occlusion with an intermittent 5 min reperfusion, and after 30 min R (NF-kB 
showed the activation maximum at 30 min R) tissue samples were taken from the ischaemic 
zone of the heart. In the control group (group 1) animals were subjected to thoracotomy and 
LAD isolation, however no ligature was applied. In the second group the preconditioning 
stimuli comprised of a single cycle of ischaemia and reperfusion (1x5 IPC). In the third group 
animals were subjected to two cycles of ischaemia and reperfusion with intermittent 5-min 
reperfusions (2x5 IPC). In the fourth and fifth group all animals underwent three (3x5) and 
four cycle of 5 min of regional ischaemia (4x5 IPC). (figure 5.) 
 
In the second series of this study we sought to block OFR by administering an antioxidant: N-
2-mercaptopropionylglicine (1.5 mg/kg/min) as a continuous infusion to any protocol. In the 
first group, acting as drug control, MPG was administered 30 min before sham thoracotomy. 
In the others MPG was infused 30 min prior to 4x5, 2x5, 3x5 or 1x5 IPC. All groups were 
administered normal saline (vehicle) infusion, starting 30 min before the procedures. (figure 
6.) 
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For NF-kB investigation (because NF-kB showed the activation maximum at 30 min R) we 
lasted 30 min reperfusion after the last cycle of PC and tissue samples were taken from the 
ischaemic zone of the heart for analysis.  
After the experimental period the heart was rapidly excised and rinsed in ice-cold 
physiological saline. The ischaemic zone was excised on the basis of the previously defined 
landmarks. The tissue was snap frozen in liquid N2, and stored for not more than 3 days at -
82°C before  EMSA analysis. 
 
4.2.3. ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
The exact method of EMSA analysis we applied in this study was described in the previous 
part of this thesis (3.2.3.).   
 
4.2.4. HAEMODYNAMICS, ARRHYTHMIAS AND FIBRILLATIONS 
Following a control measurement, ECG, heart rate and systemic blood pressures were 
registered and recorded every 15 minutes during the two-day procedure. Furthermore 
occurrence of any ventricular tachycardia and fibrillation were recorded automatically. In case 
of fibrillations, cardioversion was immediately attempted. Hearts that needed more than 3 
consecutive cardioversions to convert ventricular fibrillation were excluded from the study.  
 
4.2.5. STATISTICAL EVALUATION  
For statistical analysis EMSA pictures were appreciate with Colim 2000 Color Image 
Measuring (Pictron Kft, Hungary) densitometry software. The data (mean ± SEM) for levels 
of expression of individual protein (EMSA) were subjected to analysis of variance with post 
hoc Dunnett’s 1-tailed t-tests (NF-κB, and AP-1 EMSA), and two-sample Student’s t-test for 
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significance. Haemodynamic data were analysed using repeated measures ANOVA. The null 
hypothesis was rejected when P < 0.05.  
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Figure 5. Experimental protocol to first series of the study. (I= ischaemia, R= reperfusion) 
I R= 5 min ischaemia = 5 min reperfusion
 38
30 min reperfusion
30 min reperfusion
30 min reperfusion
30 min reperfusion
30 min reperfusion
II
I I
I I I
I I I IR R R
R R
R
GROUPS 
1
2
3
4
5
TISSUE SAMPLE 
COLLECTION 
TISSUE SAMPLE 
COLLECTION 
TISSUE SAMPLE 
COLLECTION 
TISSUE 
SAMPLE 
COLLECTION 
Figure 6. Experimental protocol to the second series of the study. (I= ischaemia, R= 
reperfusion) 
-30 min
-30 min
-30 min
-30 min
-30 min
= continuous intravenous MPG administration
I R= 5 min ischaemia = 5 min reperfusion
MPG
MPG
MPG
MPG
MPG
 39
4.3. RESULTS 
 
4.3.1. EXCLUSIONS FROM THE STUDY 
In total 6 animals were excluded from the statistical analysis of NFkB activation, leaving 60 
animals who completed the protocol. Three animals were disregarded from the 4x5 ischaemic 
preconditioning (IPC) group. Two developed intractable ventricular fibrillation (VF) during 
the last ischaemic cycle of preconditioning, and one during the early reperfusion. Two 
animals were excluded from the 3x5 IPC group due to VF that was terminal. Similarly one 
animal was excluded from the 2x5 IPC group due to persistent fibrillation.  
 
4.3.2. HAEMODYNAMICS 
Changes in heart rate, systolic and diastolic blood pressures, and rate-pressure products are 
shown in table I. The pre-ligation (control), ischaemic preconditioning (during the end of the 
ischaemic cycles), as well as early reperfusion (rep.5’) and late reperfusion (rep.30’) mean 
values are shown. Values were checked for significant variation during the time course of the 
experiment within any given group, as well as with the control group. Changes in heart rate 
did not show any significant fluctuations, even though most frequent rhythm disturbances 
were noted during early reperfusion (rep.5’). Similarly systolic and diastolic blood pressures 
only showed slight variations, however none of the changes were statistically significant. 
(table I.) 
Although MPG has been associated with a slight fall in mean arterial pressure in some 
models97, this fact is not of relevance in this study. (table II.) 
The rate pressure product, an indicator of myocardial oxygen consumption, was also fairly 
constant through out the experiments. Although few values were either significantly different 
within a group or when compared with the control group, no set pattern of change could be 
established between preconditioned and non-preconditioned animals, in either phases of the 
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study. In short, haemodynamic parameters were comparable across the groups and it is 
unlikely that changes in infarct size could be attributed to haemodynamic variations. 
 
Table I. Haemodynamic variations in the different groups of the first series. 
CONTROL 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 170.7±14.0 101.3±4.3 81.3±5.6 17,2±9,3 
PC ischaemia 165.3±8.4 98.0±7.5 73.4±7.4 16,1±9,4 
Reperfusion 5’ 157.5±5.7 96.3±15.9 78.6±17.2 15,1±6,7 
Reperfusion 30’ 168.0±13.3 103.0±14.8 87.7±25.0 17,3±4,0 
 
1x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 176.7±17.0 104.3±8.3 76.3±7.5 18,4±2,9 
PC ischaemia 169.4±9.4 88.0±7.3 64.4±3.8 14,9±7,2 
Reperfusion 5’ 162.6±6.7 104.3±13.9 80.6±15.2 16,9±5,9 
Reperfusion 30’ 171.9±11.3 109.0±9.7 92.7±14.8 18,7±3,7 
 
2x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 169.4±12.6 99.3±7.3 68.3±1.7 16,7±8,1 
PC ischaemia 164.0±13.4 93.0±7.2 74.4±3.4 15,2±5,2 
Reperfusion 5’ 152.7±8.7 106.3±7.9 79.6±6.2 16,2±3,2 
Reperfusion 30’ 158.0±7.3 103.0±11.8 86.7±5.0 16,3±7,4 
 
3x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 167.7±18.0 102.3±13.3 72.3±1.4 17,1±5,4 
PC ischaemia 162.5±11.4 82.0±14.5 64.4±3.7 13,3±2,5 
Reperfusion 5’ 169.6±5.6 97.3±15.9 80.6±17.2 16,5±2,0 
Reperfusion 30’ 153.3±7.3 106.0±7.8 92.7±14.0 16,2±9,8 
 
4x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 180.7±22.0 104.3±7.3 76.3±1.7 15.0±1.6 
PC ischaemia 153.0±13.4 88.0±7.5 64.4±3.4 11.2±1.6 
Reperfusion 5’ 154.6±5.7 104.3±15.9 80.6±17.2 13.8±2.2 
Reperfusion 30’ 154.0±13.3 109.0±14.8 92.7±14.0 15.7±2.9 
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Table II. Haemodynamic variations in the different groups treated with MPG (second series). 
 
 
MPG GROUP Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 175.5±2.7 85.3±6.3 69.3±7.7 14,9±7,0 
PC ischaemia 147.3±5.4 78.6±7.3 76.4±3.8 11,5±7,7 
Reperfusion 5’ 154.6±5.7 86.7±11.9 85.6±17.6 13,2±9,5 
Reperfusion 30’ 173.4±8.3 107.0±9.5 78.7±8.0 18,5±5,3 
 
MPG + 1x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 175.7±14.6 99.5±3.2 81.3±5.8 17,4±8,2 
PC ischaemia 168.0±8.3 88.8±5.7 66.7±7.4 14,9±8,4 
Reperfusion 5’ 159.6±5.2 103.7±11.7 70.8±17.2 16,5±5,2 
Reperfusion 30’ 163.0±7.7 97.4±22.5 86.1±22.3 15,8±7,6 
 
MPG + 2x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 169.6±4.8 93.3±4.3 81.3±4.7 15,8±6,8 
PC ischaemia 166.0±21.4 76.0±1.5 67.4±7.3 12,6±6,1 
Reperfusion 5’ 197.6±5.4 106.3±11.9 84.6±11.2 21,0±8,4 
Reperfusion 30’ 183.0±17.3 103.0±22.8 93.7±17.0 18,8±4,9 
 
MPG + 3x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic 
pressure 
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 158.7±7.6 108.3±7.3 85.3±1.7 17,1±7,2 
PC ischaemia 172.7±2.9 104.0±7.5 71.4±3.4 17,9±6,8 
Reperfusion 5’ 173.6±7.7 111.3±15.9 76.6±17.2 19,3±8,6 
Reperfusion 30’ 168.0±11.8 96.0±17.3 74.7±14.0 16,1±2,8 
 
MPG + 4x5 IPC 
GROUP 
Heart rate 
(beat/min) 
Systolic 
pressure 
(mmHg) 
Diastolic pressure
(mmHg) 
Rate pressure 
product 
(mmHg/min x 103) 
Control reading 173.7±3.0 112.3±5.2 88.3±5.7 19,3±7,6 
PC ischaemia 184.0±7.4 63.0±7.5 61.4±8.4 11,5±9,2 
Reperfusion 5’ 166.4±5.7 111.3±6.1 85.6±11.2 18,5±3,2 
Reperfusion 30’ 181.7±5.3 97.0±4.4 83.7±4.0 17,6±4,9 
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4.3.3. MEASUREMENT OF NFkB ACTIVATION 
Figure 7. (left side) shows the changes in NF-kB levels in preconditioned myocardium after 
different cycles of preconditioning ischaemia (first series of investigation). Specificity of the 
signal was verified in a competition assay wherein the signal detected by labelled NF-kB was 
abolished, when the protein homogenate was preincubated with excess unlabeled NF-kB oligo 
before the addition of labelled NF-kB. The signal was not abolished, when the compatition 
assay contained excess unlabeled non NF-kB binding oligonucleotide.   
Low and consistent levels of NF-kB were detected in normal myocardium (untreated: control 
group) at steady state. Significantly higher levels were detected after one cycle of 5 min 
ischaemia (group 1x5 IPC) compared to control (2,35 fold; p<0.05). In case of further 
repeated cycles (group 2x-, 3x-, 4x5 IPC) the NF-kB levels were significant elevated 
according to the control, but did not resulted in additional significant accretion of NF-kB rate 
compared to one cycle PC.  
 
The mean levels of NFkB in the second series of the study are depicted in Figure 7. (right 
side). The drug control group had a mean level comparable to that of the controls in series 
one. The addition of the antioxidant during the IPC protocol had little effect on the group 
preconditioned with 4 and three cycles of 5 min ischaemia, as the level of NFkB was still 
statistically significant. Adding MPG, however, abolished the previously observed NFkB 
induction with either 2x5 or 1x5 IPC. 
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Figure 7. NFkB activation rates in the first (left) and in the second (right) series of the 
study. Representative EMSA blots are showed. (upper panel)  In the graphs the results of 
the densitometry measurements are expressed as percent of control. Data are means ± 
SEM. (* means p<0,05) The values in the columns show the number of the samples. 
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4.3.4. ARRHYTHMIA AND FIBRILLATION 
Figure 8. demonstrates the tolerance to ventricular fibrillation rendered by IPC. Although we 
also monitored the incidence of arrhythmia and premature ventricular beats in every 
experiment, it can be safely claimed that no specific pattern, or significant difference was 
noted between the groups. However a distinct pattern of reduced susceptibility to VF was 
seen in most preconditioned groups.  
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4.4. DISCUSSION 
 
 
4.4.1. FREE RADICALS IN THE SIGNALING CASCADE OF PRECONDITIONING 
Our results demonstrated that oxygen radicals produced in the process of the ischaemic 
preconditioning represent an important trigger for activation of NFkB in the signaling 
mechanism of ischaemic preconditioning to act parallel with adenosine, bradyknin and the 
others. The hypothesis that oxygen free radicals may also be involved in preconditioning was 
first proposed by Murry et al98. In their experiments protection against infarction afforded by 
four cycles of ischaemic preconditioning in dogs was partially limited by the combined 
administration of the free radical scavengers Superoxide-dismutase (SOD) and catalase. In a 
subsequent study Iwamoto failed to show any alteration of protection using SOD and catalase 
in anesthetized rabbits preconditioned with four cycles of 5 min ischaemia99. In direct contrast 
to the study of Iwamoto Tanaka reported that the limitation of infarct size in in situ rabbit 
hearts could be abolished by either SOD or MPG100. The model of Tanaka was identical to 
that of Iwamoto, except for the preconditioning protocol. Tanaka used a single cycle of 
ischaemic preconditioning, whereas Iwamoto utilized four cycles. The present study clearly 
reveals that the preconditioning protocol was the cause of the divergent results.  
Consequently, our experiments in rabbits confirmed that the production of oxygen free 
radicals during the brief ischaemia-reperfusion is an important contributor to the triggering 
the signaltransduction cascade leading to NFkB activation in preconditioned myocardium. 
 
There are several possible mechanisms whereby reactive oxygen species could induce NFkB 
activity. Oxygen radicals could stimulate the protein kinase C (PKC) enzyme directly and 
Gopalakrishna and Anderson have documented that hydrogen peroxide could oxidatively 
modify the regulatory domain of PKC leading to its activation in a manner independent of 
either phosphatidylserine or calcium ions101. Consequently, - as it was described in the 
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discussion of the previous study – PKC induce the activation of NFkB through the 
phosphorylation of Inhibitor Kappa Kinase-epsilon (IKK-ε). Indirect mechanisms also exist. 
It was previously believed that mediators of preconditioning were activating PKC via the 
stimulation of phospholipase-C and hence phosphatidylinositide hydrolysis. However, recent 
evidence suggests that phospholipase-D, and not c, may be involved in the upregulation of 
PKC102. Von Ruecker et al.  have shown that membrane binding of PKC in hepatocytes is 
markedly increased following exposure to oxidative species suggesting that oxygen radicals 
can stimulate the translocation and hence activation of PKC103. It is unknown which, if any, of 
these influences on PKC accounts for the induction of NFkB transcription factor in the 
preconditioning action of oxygen radicals.  
 
 However, when multiple cycles are employed, other mediators such as adenosine and 
bradykinin appear to be released in sufficient quantities to trigger the signaling, even in the 
absence of oxygen radicals. A similar redundant mode of action has been postulated for 
bradykinin in pigs104. 
 
4.4.2. CONCLUSION 
In our experiment we demonstrated the DNA binding activities of NF-kB after different 
number of ischaemia-reperfusion (I/R) cycles. Our results show, that after one cycle of I/R – 
which was previously shown to exert powerful cardioprotective effects for ischaemic hearts – 
the activation of NF-kB increased progressively and steadily. But further clone of I/R cycles 
has not resulted in further elevation in activation of NF-kB compared to the one cycle. These 
findings correlate with Goto’s threshold hypothesis, he found that ischaemic PC is an “all or 
nothing” response to slight ischaemic-reperfusion injury. If the PC stimulus is strong enough 
to reach a “threshold” level, a full signaling cascade and protection will be induced, but in 
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cases of subthreshold stimulus the whole process will be failed. Above this threshold the 
strenght of the PC stimulus does not influence the volume of the  signaling cascade and the 
degree of the evoked cardioprotection105. (figure 9.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The authors have investigated in this study, in an animal model, that OFR are important 
triggers of delayed ischaemic preconditioning; examining NFkB induction as to show the start 
up of the signaltransduction of ischaemic preconditioning. The robust 4x5 IPC protection, 
even in the presence of MPG, as opposed to loss of protection with fewer cycles under the 
same conditions, indicates that generation of OFR is essential in triggering delayed 
cardioprotection in rabbits only when a less rigorous preconditioning stimulus is used. In 
other words, multiple cycles (4x5 IPC) may lead to the release of numerous mediators so that 
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Figure 9. Additive interaction of the triggers in ischaemic preconditioning. The 
triggers together could reach the threshold of protection and start up the signalling 
of the delayed adaptation. 
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eliminating a single trigger (in this case OFR) would not diminish the overall stimulation to a 
subthreshold level. (figure 10.) 
Nuclear Factor kappa-B activation induced by one and two cycles of ischaemic 
preconditioning was abolished by the oxygen radical scavenger MPG in in situ reperfused 
rabbit hearts, suggesting that oxygen radicals are involved in the triggering of the signaling 
cascade of ischaemic preconditioning. However MPG failed to abort NFkB induction by three 
and four cycles of ischaemic preconditioning in which accumulation of other substances could 
be sufficient to trigger the signaltransduction in the absence of oxygen radicals. 
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Figure 10. After MPG administration the triggers of one and two cycles PC were 
not enough to induce cardioprotection withouth the OFR-s. 
1x5 PC 2x5 PC 3x5 PC 4x5 PC 
 49
5. EFFECT OF ASPIRIN ON NUCLEAR FACTOR-kappa B 
ACTIVATION AND ON LATE PRECONDITIONING AGAINST 
INFARCTION IN PRECONDITIONED MYOCARDIUM 
 
 
 
 
5.1. INTRODUCTION 
 
5.1.1. GENERAL BACKGROUND 
Recent studies have demonstrated, that the NF-kB dependent gene activation can be blocked 
by sodium salicylate and by acetyl-salicylate (aspirin) in lymphoid and endothelial cells, 
through preventing phosphorylation and the subsequent proteosomal degradation of the 
inhibitor IkappaB-alpha106 107 108 109 110. 
 
 Acetylsalicylic acid (ASA) is one of the most often used nonsteroidal anti-inflammatory 
drugs applied against acute pain, fever, inflammatory diseases, and it is an important 
additional therapy for patients with ischaemic heart disease, through ASA significantly 
inhibits platelet aggregation in vivo. Thus ASA is useful in coronary artery sclerosis 
preventing the generation of thrombus on the scleroid lesions of coronary artery wall111. 
Otherwise it has been demonstrated by Shinmura et al. that ASA is able can to block late 
preconditioning in a dose dependent way. These authors presumed that this retardant effect 
could be explained by the inhibition of COX-2 activity 112. In contrast to these assumptions 
there are clinical evidences that in patients with prolonged ASA treatment significant delayed 
cardioprotection can be evoked113.  
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5.1.2. AIMS 
The aim of this study was to investigate the effect of aspirin on the NF-kB activation in the 
endogenous adaptation response of the myocardium. Accordingly, we aimed to investigate the 
effect of three different doses of acetylsalicylic acid (ASA) on the late phase of ischaemic 
preconditioning (PC) against myocardial infarction, and on the activation and nuclear 
translocation of NF-kB in the preconditioned myocardium. 
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5.2. MATERIALS AND METHODS 
 
The present study conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No.85-23, revised 1996) 
and was approved by the local institutional Committee on Animal Research of Pécs 
University (BA02/2000-29/2001). 
 
5.2.1. SURGICAL PREPARATION 
A marginal ear vein was cannulated in 60 New Zealand White rabbits weighing 2,6-3,3 kg 
(mean 2,8kg), after local anaesthesia was induced using lidocaine cream. The animals were 
anaesthetized with intravenous (iv.) xylazine (6mg/kg), ketamine (6 mg/kg) and propofol 
(10mg/kg). The trachea was intubated (tube 3 mm internal diameter) and the lungs were 
ventilated (Sulla 808, Drager, Lübeck, Germany) at a frequency of 30-35 breaths/min and a 
tidal volume of 15-20 ml. Anaesthesia was maintained by inhalation of isoflurane (2-4 Vol.%) 
and nitrous oxide (50 Vol.%). 
All surgical procedures were performed under sterile conditions, and intravenous antibiotic 
profilaxis (cephazolim, 35mg/kg) was given. Temperature was measured inside the 
pericardial cradle (Siemens Sirem, Digital Thermometer, Düsseldorf, Germany) and 
maintained between 38,3˚C and 38,7˚C by adjusting a heating pad and an infrared lamp. 
The chest was opened by midline sternotomy, and a small incision in the pericardium was 
made. The left anterior descending (LAD) coronary artery was encircled with a 5-0 prolene 
suture (Ethicon 5/0, 1-metric, TF). In general the site of vessel encirclement was on the long 
axis of the left ventricle towards the apex approximately one-fourth of the distance from the 
atrioventricular groove to the left ventricular apex. Fifteen minutes after completion of 
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surgical preparation baseline measurements were performed and animals were heparinized 
with 500 U of heparin sodium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgical preparation: 
thoracothomy, LAD isolation 
Ischaaemic preconditioning with 
LAD coronary ligature + ASA in 
selected groups. 
30 min reperfusion. 
Tissue sample collection from the 
myocardium. 
Measurement of NF-kB activation 
with EMSA. 
Thread -encircled the LAD coronary- 
was tunneled to subcutis. 
Closing the chest 
Recovery for 10 days. 
Closed chest preconditioning with 
subcutaneous thread. + ASA in 
selected groups 
Reperfusion for 24 hours. 
30 min LAD ligature (test ischaemia) 
+ 2 hours reperfusion. 
Infarct size analysis with double 
staining of the heart. 
Figure 11. Graphic algorithm of the different steps of the experiment. 
EXPERIMENTS FOR NF-KB 
ANALYSIS 
EXPERIMENTS FOR SWOP 
INVESTIGATION 
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5.2.2. EXPERIMENTS FOR NF-KB ANALYSIS  
Following the surgical preparation in the ischaemic preconditioned (PC) groups the snare was 
tightened for 4 times 5 min, thereby inducing occlusions of the coronary artery, this caused 
ischaemic preconditioning (PC) in the concerned myocardium. Myocardial ischaemia was 
readily discernible by the development of a dusky, bulging region of myocardium (careful 
note was made of anatomic landmarks of this region), and by the immediate occurrence of 
ST-segment elevations in surface electrocardiogram (ECG) (Siemens Sirecust 1260, 
Düsseldorf, Germany). Between the ischaemic cycles the heart was allowed to reperfuse for 5 
min. At the end of every 5-min period of coronary artery occlusion the suture was released to 
ensure proper reperfusion. The effectiveness of this manoeuvre was verified by the 
disappearance of the ECG changes within 2 min in every animal. 10 min before 
preconditioning in selected groups the animals were treated with intravenous acetylsalicylic 
acid (ASA) (Aspisol,Bayer AG, 51368 Leverkusen, Germany) following the experimental 
protocol. After the four cycles of ischaemia/reperfusion the animals were assigned to 30 min 
reperfusion period, and the heart was rapidly excised and rinsed in ice-cold physiological 
saline. The right ventricle and atria were trimmed away, and the left ventricle (LV) was 
divided into ischaemic and non-ischaemic zones on the basis of the previously defined 
landmarks. The tissue samples taken from the previously ischaemic region and from the 
posterior wall (nonischaemic region) were snap frozen in liquid N2, and stored for not more 
than 3 days at -82C before NF-kB analysis with EMSA and enzyme immunoassay. 
 
5.2.3. ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
The exact method of EMSA analysis we applied in this study was described in the previous 
part of this thesis (3.2.3.).   
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5.2.4. EXPERIMENTS FOR SWOP INVESTIGATION 
After the surgical preparation (described above) the threads were pulled through a reinforced 
tube (2.5 mm internal diameter, Mallinckrodt Medical, Athlone, Ireland), which was tunneled 
subcutaneously to the interscapulare space. The central end of the tube was placed close to the 
sutures around the coronary artery and fixed at the pericardium. The chest wound was then 
closed in layers and air aspirated from the thorax. Postoperative care included analgeticum 
(piritramide, 2 mg/kg, subcutaneously), mucolysis (bromhexin hydroclorid 0,1 mg/kg 
intravenous), and recovery in an isolated pen. 
 
5.2.5. LATE PRECONDITIONING 
Rabbits were allowed to recover for 10-13 days. Then, under anaesthesia we made a small 
incision above the peripherial end of the tube, and in preconditioned groups the suture was 
tightened, thereby inducing occlusion of the coronary artery. The outgrowth myocardial 
ischaemia was verified by the ST-segment aberrations in the ECG. In selected groups animals 
were treated with intravenous acetylsalicylic acid (ASA) 20min before the experimental 
protocol, and were subjected to four 5-min coronary occlusion / 5-min reperfusion cycles. For 
reperfusion the suture was released, and the complete reperfusion of the myocardium was 
verified by the disappearance of the ECG changes within 2 min in every animal. 
 
5.2.6. INFARCT SIZE ASSESSMENT 
24 hours later animals were anesthetized again with the above mentioned method. After 
median thoracotomy the suture around the coronary artery was dissected free. The animals 
were then heparinized with 500 U of heparin sodium. The rabbits were then subjected to 30 
min of coronary artery occlusion by tightening the snare. Ventricular fibrillation during 
coronary artery occlusion was treated by electrical defibrillation (5 J, DCS261 Defibrillator, 
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Piekser, Ratingen, Germany). After 30 min of occlusion the snare was released and 2 h of 
reperfusion was allowed. 
After the reperfusion period, the LAD was briefly reoccluded and patent blue dye (2ml of 1% 
cc, Byk Gulden, Konstanz) was injected into the left auricle at a constant pressure. After 
allowing for 1 more minute of circulation, the heart was excised and washed twice in cold 
saline. The atria and right ventricle were then cut away, leaving only the left ventricle. Total 
left ventricular mass was recorded. Then using fine surgical scissors the bluish non-ischaemic 
myocardium was excised from the area at risk. Area at risk –or risk zone- is the blood-supply 
area of the LAD coronary distal from the ligature. During LAD occlusion area at risk stays 
red, because Patent blue can not perfuse in this myocardium. The isolated area at risk was 
then weighed, sliced (1 mm thick) and incubated in 1% triphenyltetrazolium chloride (TTC) 
for 20 min at 37oC. The slices were then immersed in 10% formalin to enhance the contrast 
between viable (deep red) and pale, infarcted myocardium. The percentage of infarction 
within the area at risk was determined by planimetry of each slice. The volume of each zone 
was then calculated by multiplying each area by the thickness of the slice and summed up as a 
total size of infarction and area at risk in individual hearts. 
  
5.2.7. EXPERIMENTAL PROTOCOLS 
 
PROTOCOL I: EFFECT OF ASA ON THE ACTIVATION AND TRANSLOCATION OF 
NF-kB.  
Rabbits were randomly assigned into five groups. In the control group (group I, shame 
operation, 6 rabbits) animals underwent the whole surgical procedure, but the coronary artery 
was not closed. In preconditioned groups rabbits underwent 4 cycles of 5 min ischaemia / 5 
min reperfusion, inducing ischaemic preconditioning (PC) in the myocardium. In group II (6 
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rabbits) animals were subjected to 4x5 min PC without acetylsalicylic acid (ASA) treatment.  
In group III (6 rabbits) animals were treated with 5mg/kg intravenous ASA 20 min before 4x5 
min PC. 5 mg/kg is the dose of clinical antythrombotic profilaxis: significantly inhibits in 
vivo thrombocyte aggregation. In group IV (6 rabbits), before 4x5 min PC, animals were 
treated with 25 mg/kg ASA. 25 mg/kg is a high dose for analgesia and antirheumatic therapy. 
In group V (6 rabbits) animals were treated with 130 mg/kg ASA before 4x5 min PC. 130 
mg/kg is the maximum, subtoxic dose of ASA that can be used in clinical practice. (figure 
12.) 
 
PROTOCOL II: EFFECT OF ASA ON DELAYED PRECONDITIONING AGAINST 
MYOCARDIAL INFARCTION.  
Rabbits were randomly assigned into further five groups. The experiments in this protocol 
lasted for two days. On the first day animals underwent a shame operation (group VI, 6 
rabbits), or in the preconditioned group a four cycles of 5 min ischaemia / 5 min reperfusion 
(4x5 min PC, group VII, 6 rabbits). 20 min before PC rabbits were pretreated with 5mg/kg 
ASA (in group VIII, 6 rabbits), 25 mg/kg ASA (in group IX, 6 rabbits), or 130 mg/kg ASA 
(in group X, 6 rabbits). On the second day all of the animals were subjected to 30 min 
coronary occlusion and 2 hours reperfusion before infarct size analysis. (figure 13.) 
 
PROTOCOL III: EFFECT OF ASA ON PLATELET AGGREGATION. 
To prove the inhibitory effect of ASA on the platelet aggregation in rabbits we measured 
platelet function before and after administration of 5 mg/kg ASA in group III (6 rabbits).  
Three milliliters of blood were collected from the mid-dorsal ear artery into a syringe 
containing sodium citrate (Becton Dickinson Vacutainer Systems 9NC, Plymouth, UK) before 
and 60 min after the intravenous administration of 5 mg/kg ASA. After determination of 
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circulating blood cell counts, in vitro platelet aggregation was measured in stimulated whole 
blood in presence of adenosine diphosphate (ADP) and collagen with platelet aggregometer 
(Chronolog Lumi-Aggregometer M560-VS, Havertown, USA)114. 
 
5.2.8. STATISTICAL ANALYSIS 
Data are reported as mean ± SEM. Intragroup comparisons, levels of expression of individual 
protein (NF-kB EMSA) were subjected to analysis of variance with post hoc Dunnett’s 1-
tailed t-tests, and one-sample Student’s t-test for significance. Infarct size data were analyzed 
with one-way analysis of variance (ANOVA) followed by unpaired t test with Bonferroni’s 
correction for multiple comparisons. Hemodynamic data were analyzed using repeated-
measures ANOVA. Changes were considered significant when the P value was less 0,05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Experimental protocol I.  (PC = preconditioning; I = Ischaemia; R = Reperfusion; 
iv = intravenous administration.) 
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Figure 13. Experimental protocol II. (PC = preconditioning; I = Ischaemia; R = Reperfusion; 
iv = intravenous administration.) 
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5.3. RESULTS 
 
5.3.1. PROTOCOL I: EFFECT OF ASA ON THE ACTIVATION AND TRANSLOCATION 
OF NF-KB.  
Representative examples of electrophoretic mobility shift assay of NF-kB in nuclear fraction 
are illustrated in figure 14. The diagram shows changes in NF-kB levels in preconditioned 
myocardium after using various doses of ASA. Specificity of the signal was verified in a 
competition assay wherein the signal detected by labeled NF-kB was abolished, when the 
protein homogenate was preincubated with excess unlabeled NF-kB oligo before the addition 
of labeled NF-kB. The signal was not abolished, when the compatition assay contained excess 
unlabeled non NF-kB binding oligonucleotide.  
Low and consistent levels of NF-kB were detected in normal myocardium (untreated, control: 
group I) at steady state. Significantly higher levels were detected, when rabbits were 
preconditioned with four 5-min occlusion/5-min reperfusion cycles (group II) in all 6 animals 
(densitometry: 2,35-fold; p<0.001 vs. controls). The administration of low (5mg/kg) and 
medium (25mg/kg) dose ASA before ischaemic preconditioning failed to abolish the 
activation of NF-kB transcription factor. In contrast, the high dose  (130mg/kg group V) ASA 
arrested the activation of NF-kB (Fig.14, left graph). There was no change in NF-kB 
activation in the nonischaemic region among the five groups (Fig.14 , right graph). 
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Figure 14. Representative EMSA pictures showing the level of activated and translocated 
NFkB in the different groups. Densitometric measurements of NFkB on the EMSA pictures 
were expressed as a percentage of the average value measured in the control rabbits. The two 
comparisons performed in each panel were adjusted by the Bonferroni correction. Data are 
means ± SEM. (ASA=acetylsalicylic acid, PC= preconditioning) 
 
 
5.3.2. PROTOCOL II: EFFECT OF ASA ON DELAYED PRECONDITIONING AGAINST 
MYOCARDIAL INFARCTION.  
There were no significant differences in the heart rate, systemic blood pressures or 
rate/pressure product (not shown) among the five (VI.-X.) groups. Table III. summarizes 
changes in heart rate at selected intervals during both first and second day of the experiments.  
Ischaemic risk zone volume and infarct size are shown in table IV. Ischaemic risk zone 
volume was similar in all experimental groups at around 19% to 23% of the left ventricle 
mass. Infarct size as a percentage of the risk zone is demonstrated in figure 15. Sham-operated 
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control rabbits (group VI.) had a mean infarct size of 61,3 ± 12,3% of the risk zone. 
Preconditioning (PC) with four 5-min coronary occlusion episodes limited the infarction to 
32,7 ± 8,6% (p<0,05) in group VII. Pre-treatment of the animals before PC with 5 mg/kg 
ASA (group VIII.) and with 25 mg/kg ASA (group IX.) did not influenced the protective 
effect of late PC, and resulted in 34,6 ± 8,7% and 36,4 ± 9,3% infarct/risk ratio. In contrast, 
pre-treatment with 130 mg/kg ASA (group X.) prior to PC abolished the cardioprotection and 
lead to an infarct size of 59,1 ± 11,6%. Thus, protection against infarction was observed 24 h 
after PC with 4x5min coronary artery occlusion, and this protective effect was significantly 
blocked with a high dose (130 mg/kg) of ASA treatment prior to the PC stimuli. 
 Arrhythmias during the PC procedure on the first day were rare and minor in nature. 
Although the majority of animals in all groups experienced some form of ventricular 
premature beats and/or ventricular tachycardia (VT) (data not shown), their extent was highly 
variable, and no specific pattern could be determined. Fewer animals had ventricular 
fibrillation (VF) during the ischaemia-reperfusion period, overall, there were no statistically 
significant differences in VT or VF across the groups. 
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Table III. Heart Rate (beats/min) during the PC on first day and ischaemia-reperfusion on 
second day. Values are means ± SEM. 
 (Baseline = before administration of ASA; Before PC = just before the first ischaemic period 
of preconditioning; PC1 = end of the first ischaemic cycle of preconditioning; PC4 = end of 
the fourth ischaemic cycle of preconditioning; second day control = on the second day before 
surgical procedur;e ASA = acetylsalicylic acid) 
 
 
 
 
Table IV. Size of ischaemic-reperfused (risk) zone. Values are means ± SEM. (ASA = 
acetylsalicylic acid; PC = preconditioning; LV = left ventricle; *= significant) 
 
 
 
 
 
Group 6 
(control) 
(6 animals) 
Group 7 
(PC) 
(6 animals) 
Group 8 
(PC+5ASA) 
(6 animals) 
Group 9 
(PC+25ASA) 
(6 animals) 
Group10 
(PC+130ASA)
(6 animals) 
 
Body weight (g) 
 
2869 ± 97 
 
 
2765 ± 125 
 
2925 ± 89 
 
2874 ± 65 
 
2831 ± 139 
 
LV weight (g) 
 
 
3,77 ± 0,25 
 
4,13 ± 0,17 
 
4,06 ± 0,21 
 
3,92 ± 0,15 
 
4,26 ± 0,28 
 
Area at risk (g) 
 
 
0,81 ± 0,08 
 
0,79 ± 0,07 
 
0,87 ± 0,05 
 
0,91 ± 0,09 
 
0,84 ± 0,10 
 
Risk-to-LV ratio 
(%) 
 
21,5 ± 2,8 
 
19,1 ± 3,1 
 
21,4 ± 2,9 
 
23,2 ± 3,2 
 
19,7 ± 3,5 
Infarct size-to 
risk zone ratio 
(%) 
 
61,3 ±12,3% 
 
32,7 ± 8,6%*
 
34,6 ± 8,7%*
 
36,4 ± 9,3%* 
 
59,1 ± 11,6% 
 
 
Heart rate 
(Beats/min) 
Baseline Before PC PC 1 PC 4 Second 
day 
control 
Ischaemia 
30 min 
Reperfusi
on 2 h 
Group 6 
(control) 
- 237±9 252±5 248±9 226±11 247±9 234±8 
Group 7  
(PC) 
- 245±6 257±5 251±9 237±4 252±11 236±14 
Group 8 
(PC+5ASA) 
244±9 232±12 239±7 238±11 228±9 249±12 231±11 
Group 9 
(PC+25ASA) 
253±6 241±5 251±15 247±13 234±13 237±6 228±7 
Group 10 
(PC+130ASA) 
248±7 229±7 236±8 235±14 233±8 241±15 232±13 
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Figure 15. Infarct size: infarct size as a percentage of the area at risk. * p<0,05.  (PC = 
preconditioning; ASA = acetylsalicylic acid) 
 
5.3.3. PROTOCOL III: EFFECT OF ASA ON PLATELET AGGREGATION.  
There were no significant differences in the number of white blood cells, platelets and red 
blood cells before and after the administration of 5 mg/kg ASA (table V). After ASA 
treatment the values decreased slightly, but not significantly in all categories, probably due to 
the diluting effect of the intravenous infusion and the blood sampling. With collagen 
induction the platelet aggregation was suppressed by low dose (5 mg/ kg) ASA. In contrast, 
platelet aggregation in response to ADP was unchanged after low dose ASA. That 
demonstrates, that the inhibitory effect of ASA (5mg/kg) on platelet aggregation is similar in 
rabbits and in humans. (table V.) 
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Table V. Complete blood count and platelet aggregation before and after ASA treatment in 
rabbits of group III.  
Values are means ± SEM. ASA = acetylsalicylic acid; ADP = adenosine diphosphate. 
 
 
 
 
 
 Baseline 
After ASA (5 
mg/kg iv) Units P Value 
 
Complete Blood Count 
 
White blood cells 7,3 ± 0,5 7,0 ± 0,4 103/ml NS 
Red blood cells 5,52 ± 0,06 5,19 ± 0,06 106/ml p<0,05 
Hemoglobin 12,0 ± 0,4 11,5 ± 0,4 G/dl NS 
Hematocrit 35,4 ± 0,8 34,1 ± 1,1 % NS 
Platelets 231 ± 22 217 ± 23 103/ml NS 
 
Platelet Aggregation Test 
 
ADP (at 6 min) 9,3 ± 0,46 8,2 ± 0,38 Ω NS 
Collagen (at 6 
min) 
21,3 ± 2,4 14,6 ± 1,9 Ω p<0,05 
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5.4. DISCUSSION 
 
5.4.1. THE QUANDARY: ASPIRIN, COX-2 AND CARDIOPROTECTION 
An obvious question is, whether ischaemic preconditioning is a clinically relevant 
phenomenon, that is, whether brief bouts of ischaemia evoke a protective phenotype in 
patients at risk of suffering acute coronary events. In this regard, current evidence, although 
not definitive, favors the conceptthat, as in the experimental laboratory, brief episodes of 
antecedent ischaemia may confer both an early and delayed phase of endogenous 
cardioprotection in the human heart115 116 117. However, if the conclusions regarding the 
crucial role of COX-2 in delayed PC derived from experimental models can be explorated to 
the clinical arena, this raises a disturbing possibility: the benefits of delayed PC may, in 
concept, be compromised in patients using the COX inhibitor acetylsalicylic acid (ASA; 
aspirin) for relief of fever, pain, and inflammation and, perhaps of greatest concern, in the 
countless patients prescribed ASA for the prophylactic prevention of acute myocardial 
infarction and stroke118 119 120. Moreover, as the protective role of prostanoids is not limited to 
the delayed second window of preconditioning – there is experimental evidence implicating 
the involvement of endogenous prostaglandins in infarct size reduction in some models121 of 
early, first window of PC, in the protection afforded by angiotensin-converting enzyme 
(ACE) inhibitors against postischaemic myocardial stunning122 123, and in the reduction of 
infarct size seen with angiotensin A1 receptor blockers124 – ASA therapy may adversely 
effect these other cardioprotective modalities. In fact, retrospective analyses of large clinical 
trials have suggested that the prophylactic use of ASA may deprive the postmyocardial 
infarction patient125. It is not, however, clear from these analyses whether the potential loss of 
benefit related to antithrombotic, analgesic or antirheumatic doses of ASA. 
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5.4.2. EFFECT OF ESCALATING DOSES OF ASA ON THE ACTIVATION OF NFkB 
AND ON THE LATE PC AGAINST MYOCARDIAL INFARCTION 
In clinical practice ASA is used at three different dosage levels, with each dose reflecting the 
relative ASA sensitivity of different target cells126. ASA acts as an antithrombotic (60 to 325 
mg per day), as an analgesic/antipyretic (650 mg), or as an antirheumatic agent (3000 to 6000 
mg). We chose 5 mg/kg as the low dose because this dosage is comparable to that used to 
prevent cardiovascular events in patients127. We found that this dose of ASA inhibited platelet 
aggregation (a COX-1-dependent phenomenon) but had no effect on NFkB induction 
followed the brief ischaemic-reperfusion episodes of PC (COX-2-dependent phenomenon and 
had no effect on late PC against myocardial infarction. We also evaluated the antirheumatic 
dose of aspirin (25 mg/kg) and nor NFkB activation neither late cardioprotection was blocked. 
Taken together, these results indicate that doses of ASA commonly given to patients (5 to 25 
mg/kg) do not interfere with late PC. 
 
In a recent report of Shinmura et al. extend their previous work and address the question of 
ASA therapy and cardioprotection in a conscious rabbit model of late PC against myocardial 
stunning128. Using a multigroup and multidisciplinary study design, the primary end point of 
late PC against stunning was quantified by measurement of systolic wall thickening, and 
myocardial COX-2 levels were determined by Western immunoblotting. Shinmura reported 
that a single, low-dose administration of ASA (5mg/kg), designed to mimic clinical 
antithrombic therapy (typical daily dose of 75 to 325 mg) and confirmed by the authors to 
inhibit in vitro platelet aggregation, attenuated the increase in COX-2 activity seen with brief 
antecedent PC ischaemia. Most importantly, however, low dose ASA, despite its partial 
inhibition of COX-2 activity, did not block the favorable, delayed PC response129. 
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The ability of ASA to prevent platelet aggregation and, thereby, prevent cardiac and cerebral 
ischaemia, results from inhibition of COX-1 due to irreversible acetylation of the protein at 
serine 530130 131. ASA also inhibits COX-2 in a similar manner but exhibits less potency for 
COX-2 than for COX-1132 because the substrate channel of COX-2 is larger and more flexible 
than that of COX-1133. These considerations provide a plausible explanation for our finding 
that 5mg/kg of ASA inhibited platelet aggregation but failed to affect late PC. 
In contrast with the effect of antithrombotic and antirheumatic doses of ASA, administration 
of the subtoxic dose of ASA (4-8000 mg per day; maximum subtoxic serum level: 150-300 
microg/ml), 130 mg/kg, blocked the induction of the transcription factor NFkB and 
completely ablated the beneficial action of late PC on myocardial infarction, suggesting that 
they should be used with caution in patients with atherosclerotic cardiovascular disease 
because they may deprive the hearts endogenous adaptation capability. Given the ubiquitous 
use of ASA and other NSAIDs and the increasing use of selective COX-2 inhibitors, the 
present findings have potential clinical reverberations. Recent studies indicate that COX-2 
inhibitors increase the incidence of cardiovascular events134 135, possibly because they inhibit 
late PC (a COX-2 dependent phenomenon) without inhibiting platelet aggregation (a COX-1 
dependent phenomenon)136. Because many NSAIDs, such as ibuprofen and indomethacin, are 
less COX-1 selective than ASA137, they may interfere with late PC at relatively lower doses. 
Our result suggest that the actions of NSAIDs in patients with atherosclerosis are more 
complex than heretofore appreciated, and that when NSAIDs are given in dosis sufficient to 
block COX-2, inhibition of the PC response may offset the benefits deriving from inhibition 
of platelet aggregation. 
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5.4.3. CONCLUSIONS OF OUR STUDY 
Our study provides the first experimental insight into the consequences of nonsteroidal anti-
inflammatory therapy on the efficacy of the delayed PC against myocardial infarction, and 
yields three important observations: 
 
The administration of a low dose of ASA (5mg/kg), which is sufficient to inhibit platelet 
aggregation, does not block NFkB activation and does not ablate the cardioprotective effect of 
late PC. 
Higher doses of ASA, in the range used for analgesic/antipyretic and antirheumatic effects (25 
mg/kg), also do not block NFkB activation and late PC. 
In contrast, a very high dose of ASA (the subtoxic, maximally allowed daily dose: 130 
mg/kg) abrogates the activation and nuclear translocation of transcription factor NFkB, and 
completely blocks the cardioprotection afforded by late PC. 
 
These results suggest that, in patients taking ASA, the ability of the myocardium to shift to a 
preconditioned phenotype is not impaired so long as these drugs are given in low and medium 
doses, however, high doses of ASA that completely block NFkB activation, can deprive the 
heart of its innate defensive response. 
 
5.5.4. EXPERIMENTAL AND CLINICAL CONSIDERATIONS 
Despite the comprehensive protocol design there are two caveats that warrant consideration in 
the interpretation of our data. First, in addition to the care that must always be exercised in the 
extrapolation of experimental studies to the clinical setting, it must further be acknowledged 
that the single, low-dose administration of aspirin in our rabbit model does not fully mimic 
the long-term, daily aspirin therapy prescribed to patients for the primary or secondary 
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prevention of cardiovascular events. Second, although the age of the rabbits was not specified, 
our study was conducted in adult animals. The effect of increasing age on the delayed, 
“second window” of PC are at present unknown, however, concerns have emerged that, in 
some models, the efficacy of the early protection may wane, or be lost in senescent cohorts138 
139 140 141, while, in other species (i.e., rabbit), recent evidence suggest that the cellular 
mechanisms responsible for early PC may differ in adult versus old animals142 143. As the 
aging cohort is, without question, precisely the population in which the incidence of acute 
ischaemic events is greatest and, thus, cardioprotection by any means (including both PC and 
prophylactic aspirin therapy) is most germane, future studies focusing on delayed PC in old 
animals, with versus without aspirin therapy, would be of considerable interest and relevance. 
 
In addition to these aforementioned issues, the current result raises several other compelling 
questions. For example, the widespread clinical use of other nonsteroidal anti-inflammatory 
agents with greater COX-2 specificity (i.e., ibuprofen, naproxen) and growing popularity of 
recently developed COX-2.specific inhibitors (celexocib, rofexocib)144 begs the question: do 
agents that more closely target COX-2 undermine the endogenous, late phase of 
cardioprotection conferred by brief antecedent ischaemia? This concept may, again, be of 
particular relevance in aging cohorts. Finally, although prospective clinical evaliation of these 
issues would be daunting, a retrospective analysis of surrogate indexes of delayed, “second 
window” preconditioning, incorporating use of nonsteroidal anti-inflammatory agents as a 
covariate, may provide a more feasible approach to explore the clinical implications of the 
“COX-2 hypothesis of late PC”. All of these concepts would build upon our observations, and 
represent fruitful lines of future investigation. 
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Figure 15. (next page) Effect of ASPIRIN on the intracellular signaling mechanism of 
ischaemic preconditioning.   
(NO-nitric oxide; ROI-reactive oxygen intermediers; ONOO-peroxinitrit;  PLC and PLD-
phospholipase C and D; PIP2-phosphatitil/inositol/ diphosphate; Ip3-inositol triphosphate; 
DAG-diacilglicerol; PKC-protein kinase  C; IKK-inhibitor  kappa kinase; MAP kinase-
mitogén aktivated protein kinase; TyrK-tyrozin kinase; NFkB-nuclear factor-kappaB; iNOS-
inducible nitric oxide synthase; MnSOD- manganese  superoxide-dismutase)
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6. DISCUSSION AND CLINICAL RELEVANCES 
 
 
6.1 PRECONDITIONING THE HUMAN HEART 
 
The evidence in support of the occurrence of the preconditioning phenomenon in human 
myocardium arises from laboratory and clinical experiments. Studies in isolated human 
ventricular myocytes145, and isolated atrial trabeculae146 both suggest that protection can be 
induced in vitro using metabolic and functional end-points respectively. In the clinical setting 
there is some evidence to suggest that preconditioning may occur naturally. Patients suffering 
angina prior to a myocardial infarction have a better in-hospital prognosis, a reduced 
incidence of cardiogenic shock and congestive cardiac failure, and smaller infarcts as assessed 
by release of cardiac enzymes147. The phenomenon of warm-up angina, in which patients 
complain that their anginal symptoms are worse in the morning but improve during the course 
of the day has been studied148. There is evidence of increased efficiency of myocardial 
metabolism during a second episode of exercise in terms of reduced oxygen consumption at a 
given work load as well as less anginal symptoms and ST segment changes. PTCA studies, in 
which the effect of serial balloon inflations can be examined, have provided further support149 
but, as with all of the above examples, results may be confounded by the effects of collateral 
recruitment despite efforts to control for this effect150.  
More direct evidence for preconditioning in man has emerged from a study in patients 
undergoing cardiac surgery in which resistance to global ischaemia was assessed151. In this 
situation changes in collateral flow do not play a role. Intermittent application of the aortic 
cross clamp was used to deliver repeated episodes of global ischaemia to provide the 
preconditioning stimulus. Patients subjected to this protocol had better preservation of ATP 
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levels in myocardial biopsies during a subsequent 10 minute global ischaemic period. These 
metabolic changes were almost identical to those seen in dogs by Jennings group152. 
However, as discussed later, total myocardial ATP content may not reflect local turnover 
within subcellular compartments, and certainly does not provide information about the 
efficiency of cellular metabolism in terms of ATP requirements. In a more recent study153, 
involving a larger group of patients, serum levels of troponin-T were used as an indicator of 
myocardial cell necrosis. Using this end-point, patients subjected to the same preconditioning 
protocol suffered less necrosis as determined by release of troponin-T. Of considerable 
interest, however, was the finding that the ATP levels did not differ between preconditioned 
and control groups. This emphasises the need for multiple end-points to be used, especially in 
studies where small differences in myocardial viability without overt clinical effects are 
expected.  
 
6.1.1. WHO SHOULD WE TREAT WITH THERAPEUTIC APPROACHES BASED ON 
PRECONDITIONING? 
It would appear from the evidence outlined above that human myocardium is amenable to 
preconditioning and that preconditioning may occur as a natural feature of some ischaemic 
syndromes. However, even with the development of pharmacological agents that can mimic 
or evoke the protection of ischaemic preconditioning, the timing of administration will be 
critical. Prompt reperfusion will always remain the most effective method of limiting 
ischaemic injury and is, therefore, the most important determinant of prognosis. However, 
there are certain situations in which the timing of treatment before the onset of ischaemia can 
be controlled to some extent.  
Patients presenting with unstable angina are at high risk of myocardial infarction and would 
form a reasonably well-defined group for pre-emptive treatment. A therapy that stimulated or 
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augmented the cellular preconditioning mechanisms over a period of several days or weeks 
could keep the myocardium protected. In the event of the patient suffering an acute 
myocardial infarction the treatment would enhance tissue tolerance and slow the rate of 
necrosis. Such a treatment would `buy time' for the administration of revascularisation 
therapies. A major theoretical hurdle is maintaining myocardium in a protected state by 
preconditioning. Experiments in Downey"s laboratory suggest that continuous adenosine A1 
receptor activation with high dose chronic infusion of CCPA leads to down-regulation of the 
signalling mechanism and loss of protection154. However, more encouraging data have been 
obtained recently using a different dosing schedule. CCPA was administered to rabbits by 
intermittent dosing over a 10 day period, and the persistence of myocardial protection 
assessed 48 hours after the final dose. The expected down-regulation of adenosine A1 
receptors was not observed (since the haemodynamic responses to administration of the 
agonist were preserved) and infarct size remained significantly reduced in the drug treated 
group155.  
Preconditioning strategies might also be applied prior to a planned procedure involving a 
potentially injurious ischaemic insult. An example is coronary artery bypass graft (CABG) 
surgery. Highly effective strategies for myocardial preservation have already been developed 
including the use of various cardioplegic solutions, topical and systemic hypothermia, and 
intermittent aortic cross-clamping with ventricular fibrillation. In general, the rationale behind 
the use of cardioplegic techniques includes rapid diastolic arrest, membrane stabilisation, 
hyperosmolarity (to prevent intracellular oedema), acid buffering, and hypothermia. 
Additional strategies such as continuous coronary perfusion, warm instead of cold 
cardioplegia (to avoid cold injury), and the use of blood instead of crystalloid solutions (to 
improve oxygen delivery) have all added to the choices available to the cardiac surgeon. 
Having said that present cardioprotective measures are highly effective at minimising 
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irreversible injury that might occur during these periods of imposed ischaemia, they are not 
without their limitations. Even with carefully controlled intra-operative ischaemic periods and 
hypothermia, sensitive markers of tissue injury such as troponin-T indicate that discrete 
necrosis occurs156 157 158 159. Moreover, as surgeons undertake more complex and higher risk 
operations, so the need for better preservation methods increases. In a situation like CABG, 
the administration of an agent prior to surgery that could enhance myocardial defences would 
reduce susceptibility to focal necrosis during surgery and permit the extension of the intra-
operative ischaemic period. High risk patients with poor pre-operative left ventricular 
function might certainly benefit if the degree of protection could be improved by invoking 
endogenous cellular adaptive mechanisms. The possibility that organ preservation prior to 
transplantation might be amenable to the same improved protection is also of significant 
interest.  
 
6.1.2. CLINICAL ENDPOINTS FOR ASSESSMENT OF EFFICACY 
Any clinical trial involving the use of a potential pharmacological agent designed to mimic 
the protection of ischaemic preconditioning will have to demonstrate its value in terms of 
relevant clinical end-points such as preservation of left ventricular function, attenuation of 
stunning, need for inotropic or balloon support, incidence of clinically detectable infarction, 
left ventricular failure, and post-operative death. However, studies so far have concentrated on 
low risk patients with good pre-operative status that would be expected to do well in any 
event. The benefit derived from ischaemic preconditioning in this group of patients is likely to 
be marginal. The end-points used presently are relatively insensitive; they provide us with 
indirect information on myocardial viability and are no substitute for direct measurement of 
infarct size. Measurement of total myocardial ATP content is not universally accepted as a 
sensitive marker of cell viability and the concept of a critical tissue concentration of ATP, 
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below which cell death occurs, is now known to be incorrect160. If it were possible to measure 
sub-cellular levels of ATP within different compartments (such as the mitochondrial fraction), 
and thereby assess local turnover, then more useful information might be available. End-
points of clinical outcome are more likely to demonstrate a difference in studies conducted in 
a group of patients at higher risk, but these can only be performed once safety and tolerability 
have been established.  
 
6.1.3. REMOTE PRECONDITIONING AND STRETCH-INDUCED PRECONDITIONING 
Stimuli other than ischaemia of the myocardial risk territory may confer cardioprotection 
against damage by subsequent coronary artery occlusion. Brief circumflex coronary 
occlusions in canine myocardium induce protection of remote myocardium subtended by the 
left anterior descending coronary artery, suggesting that unidentified diffusible factors or 
neuronal mechanisms may influence remote tissue161. A further, and more intriguing, example 
of remote preconditioning is that brief renal ischaemia or mesenteric artery occlusion leads to 
protection against coronary artery occlusion162. The mechanisms of `inter-organ' 
preconditioning are unknown but it is possible that there is a neuronal component. Transient 
stretch of myocardium by acute volume overload has been shown to confer protection against 
myocardial ischaemia by Ovize and co-workers163. This phenomenon is abolished by 
gadolinium, a stretch activated ion channel blocker, and by a PKC blocker164. These 
investigations expand the strictly defined concept of ischaemic preconditioning.  
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6.2. CLINICAL CONCLUSION 
 
Direct activation of the cellular pathways involved in ischaemic preconditioning by 
pharmacological manipulation would allow improved myocardial protection without the need 
for an ischaemic preconditioning insult. A clear understanding of the mechanisms involved in 
either form of protection (early or late) is essential to allow a reasoned approach to drug 
design.  
There are several classes of pharmacological agents that may be able to mimic the protection 
conferred by ischaemic preconditioning and provide some basis for optimism that a beneficial 
and clinically detectable improvement in myocardial protection may be possible.  
In conclusion, we feel that exploitation of endogenous cardioprotective mechanisms may be 
possible in the context of carefully conducted clinical studies. There have been significant 
advances in our understanding of the mechanisms underlying ischaemia-reperfusion injury as 
a result of preconditioning research and potential pharmacological approaches to protection 
seem feasible. However further development of pharmacological therapies should be based on 
sound experimental investigation and assessed in the context of other effective therapeutic 
strategies.  
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7. NOVEL FINDINGS 
 
Our result shows a biphasic increase of Nuclear Factor-kB activation, with peak levels at 30 
min and at 3 hour of reperfusion in preconditioned myocardium. Induction of Activation 
Protein-1 increased monophasically, with peak level at 1 hour of reperfusion. Our results 
shows that the activation of NFkB and AP-1 have a specific time curve after ischaemic-
reperfusion stimulus, and suggest that the regulation of these two transcription factors in the 
signalling of ischaemic preconditioning are different. 
 
We have demonstrated, that one cycle of ischaemia induced a significant increase of NFkB 
and AP-1 activation in the preconditioned myocardium. Further repetition of ischaemia-
reperfusion cycles has not resulted in further elevation in activation of NF-kB and AP1 
compared to the one cycle. These findings demonstrate that the activation of these 
transcription factors in the signaltransduction of ischaemic PC is an “all or nothing” response. 
If the PC stimulus is strong enough to reach a “threshold” level, a full signaling cascade and 
protection will be induced. Above this threshold the strenght of the PC stimulus does not 
influence the volume of the signaling cascade and the degree of the evoked cardioprotection. 
 
In our experiments we were able to demonstrate that oxygen radicals are involved in the 
triggering of the signaling cascade of ischaemic preconditioning and in the induction of the 
transcription factor NFkB in the preconditioned myocardium in an in vivo rabbit model. 
Oxygen free radicals act in concert with the other triggers of ischaemic preconditioning 
confirming the additive interaction between the triggers of the endogenous cardioprotection. 
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Our results demonstrated firstly that the administration of a low dose of ASA (5mg/kg), 
which is sufficient to inhibit platelet aggregation, does not block NFkB activation and does 
not ablate the cardioprotective effect of late PC. Higher doses of ASA, in the range used for 
analgesic/antipyretic and antirheumatic effects (25 mg/kg), also do not block NFkB activation 
and late PC. In contrast, a very high dose of ASA (the subtoxic, maximally allowed daily 
dose: 130 mg/kg) abrogates the activation and nuclear translocation of transcription factor 
NFkB, and completely blocks the cardioprotection afforded by late PC. 
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